AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Invivyd's REVOLUTION program for VYD2311 advances, but analysts see no shift in long-term revenue growth outlook.
ByAinvest
Friday, Dec 19, 2025 1:30 am ET1min read
Invivyd's latest clinical progress has left its fair value estimate at $10.00 per share, with a slight uptick in the discount rate indicating a modest shift in perceived risk. Analysts interpret the stable long-term revenue growth outlook as reinforcement of expectations for VYD2311's potential to reshape Invivyd's market opportunity. H.C. Wainwright doubled its price target to $10, signaling improved confidence in Invivyd's execution and long-term growth prospects in COVID-19 prevention.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet